Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2022-12-05 Regulatory Filings
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PHARMANUTRA S.P.A. COMPLETES AKERN S.R.L. ACQUISITION
Regulatory Filings Classification · 1% confidence The document is an official communication from PHARMANUTRA S.P.A. dated December 5, 2022, identified by the header 'Informazione Regolamentata n. 20106-62-2022' and the type 'REGEM'. The subject is 'PHARMANUTRA S.P.A. COMPLETES AKERN S.R.L. ACQUISITION'. This announcement details the completion of a strategic acquisition (M&A activity) and the subsequent change in ownership structure. While it relates to a transaction, the core event being reported is the finalization of the acquisition, which falls under Merger & Acquisition (M&A) activity. However, the provided categories do not have a specific M&A code. The closest relevant categories are 'TAR' (M&A Activity) or 'RNS' (Regulatory Filings/General Announcement). Since the document explicitly details the completion of a takeover/acquisition process, 'TAR' (Transaction/Merger/Acquisition) is the most specific fit among the options, even though the definition for TAR is 'Merger proposals or takeover bids'. Given the context of corporate actions, this announcement of a completed acquisition is best classified as M&A activity. If 'TAR' is strictly interpreted as only proposals/bids, then 'RNS' would be the fallback. Based on the content describing the completion of an acquisition, I will classify it as M&A Activity (TAR).
2022-12-05 English
PHARMANUTRA PARTNERS WITH THE LUNA ROSSA PRADA PIRELLI TEAM FOR THE 37th EDITION OF THE AMERICA’S CUP
Environmental & Social Information Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. announcing a new partnership with the Luna Rossa Prada Pirelli sailing team for the America's Cup. The text details the nature of the sponsorship, the involvement of the Cetilar® brand, and the launch of a 'Human Performance project.' This type of announcement, detailing a significant business development or sponsorship agreement, does not fit the specific financial reporting categories (10-K, IR, ER, etc.). It is a general corporate announcement. Since it is not a management change (MANG), financing event (CAP), or insider trade (DIRS), the most appropriate general category for a significant, non-standard corporate event announcement is 'Regulatory Filings' (RNS), which serves as a broad category for official corporate news releases that don't fit elsewhere, especially given the structure resembling a formal regulatory disclosure ('Informazione Regolamentata').
2022-11-15 English
PHARMANUTRA INSIEME A LUNA ROSSA PRADA PIRELLI TEAM PER LA 37^ EDIZIONE DELL’AMERICA’S CUP
Regulatory Filings Classification · 1% confidence The document is a formal announcement dated November 15, 2022, originating from PHARMANUTRA, classified as 'Informazione Regolamentata' (Regulated Information) in Italy. The subject ('Oggetto') is the announcement of a sponsorship partnership between PharmaNutra and the Luna Rossa Prada Pirelli sailing team for the 37th America's Cup. The text details the nature of the partnership, the launch of the 'Human Performance' project, and includes quotes from management. This type of announcement, detailing a significant business development (sponsorship/partnership) that is material to investors, is typically classified as a general regulatory announcement or a specific corporate action announcement. Since it is not a financial report (10-K, IR, ER), a management discussion (MDA), or a capital change (CAP, SHA), it fits best under the general category for regulatory disclosures that aren't covered by the more specific codes. Given the context of a formal, regulated disclosure about a strategic business event, 'Regulatory Filings' (RNS) is the most appropriate fallback, although 'LTR' (Legal Proceedings Report) or 'TAR' (M&A Activity) are clearly incorrect. It is not a Report Publication Announcement (RPA) because it *is* the content of the announcement, not just a notice that a report is available. Therefore, RNS is the best fit.
2022-11-15 Italian
INTERIM FINANCIAL REPORT AS AT 30 SEPTEMBER 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM MANAGEMENT REPORT' and covers the period ending 30th September 2022. It contains detailed consolidated financial statements (Balance Sheet, Income Statement, Cash Flow Statement), explanatory notes, and management analysis of business performance. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 English
PHN - RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RESOCONTO INTERMEDIO DI GESTIONE' (Interim Management Report) for the period ending September 30, 2022. It contains comprehensive financial statements, including the consolidated balance sheet, income statement, and cash flow statement, along with detailed management commentary on business performance, acquisitions (Akern S.r.l.), and market trends. It is a formal financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2022
2022-11-14 Italian
PR - BoD APPROVES INTERIM MANAGEMENT REPORT AS AT 30 SEPTEMBER 2022
Report Publication Announcement Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. announcing the approval of its Interim Management Report for the period ending September 30, 2022. While it contains summary financial tables and highlights, it is structured as a corporate announcement (press release) rather than the full, formal interim report itself. According to the 'Menu vs Meal' rule, this is an announcement of the report's approval and contents, which fits the definition of a Report Publication Announcement (RPA). 9M 2022
2022-11-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.